K2M Group (KTWO) Updates FY17 Earnings Guidance
K2M Group (NASDAQ:KTWO) updated its FY17 earnings guidance on Monday. The company provided earnings per share guidance of -0.86 to -0.81 for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.85). The company issued revenue guidance of $257.5-258.1 million, compared to the consensus revenue estimate of $255.93 million.
K2M Group (KTWO) traded up $0.66 during trading on Monday, reaching $19.85. The company had a trading volume of 62,104 shares, compared to its average volume of 398,025. K2M Group has a fifty-two week low of $16.44 and a fifty-two week high of $25.99. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.06 and a quick ratio of 1.67. The company has a market capitalization of $855.31, a PE ratio of -20.68 and a beta of 1.34.
K2M Group (NASDAQ:KTWO) last posted its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). K2M Group had a negative return on equity of 16.02% and a negative net margin of 16.22%. The business had revenue of $62.65 million for the quarter, compared to the consensus estimate of $62.69 million. During the same quarter in the previous year, the business posted ($0.19) EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. sell-side analysts anticipate that K2M Group will post -0.85 earnings per share for the current year.
A number of equities analysts recently commented on KTWO shares. Royal Bank of Canada reiterated a buy rating and set a $26.00 price target on shares of K2M Group in a report on Friday, September 22nd. Piper Jaffray Companies reiterated a buy rating and set a $28.00 price target on shares of K2M Group in a report on Thursday, September 28th. Zacks Investment Research upgraded K2M Group from a hold rating to a buy rating and set a $25.00 price target for the company in a report on Wednesday, October 4th. Needham & Company LLC reiterated a strong-buy rating and set a $27.00 price target (down previously from $29.00) on shares of K2M Group in a report on Monday, October 9th. They noted that the move was a valuation call. Finally, ValuEngine cut K2M Group from a hold rating to a sell rating in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $24.40.
About K2M Group
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with Analyst Ratings Network's FREE daily email newsletter.